Limited success of HCV antiviral therapy in United States veterans

American Journal of Gastroenterology

Volumn 97, Issue 1, 2002, Pages 149-155

  Cawthorne, Cathey H ^b   Rudat, Kelly R ^b   Burton, Mary S ^b   Brown, Kyle E ^b   Luxon, Bruce A ^b   Janney, Christine G ^b   Fimmel, Claus J ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; REBETRON; RIBAVIRIN;

ADULT; ARTICLE; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; RISK FACTOR; SOLDIER; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGE DISTRIBUTION; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; TREATMENT FAILURE; UNITED STATES; VETERANS;

EID: 0036140584     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)04001-1     Document Type: Article

References (25)

1. Epidemiology of hepatitis C virus infection in American veterans
2. Natural history of liver fibrosis progression in patients with chronic hepatitis C
3. Seroepidemiology of hepatitis C and B in an urban VA medical center
4. Hepatitis B and hepatitis C in emergency department patients
5. Classification of chronic viral hepatitis: A need for reassessment
6. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C
7. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
8. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C
9. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis
10. Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
11. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
12. How often are referred chronic hepatitis C patients candidates for antiviral therapy?
13. Hepatitis C thetapy in treatment-naïve patients
14. Management of interferon relapsers
15. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
16. Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to interferon therapy
17. Blood-borne viral infections in patients with von Willebrand disease: Prevalence and clinical correlation
18. Final results of the Washington, DC metropolitan area hepatitis C investigators study of Intron-A plus ribavirin (Rebetron) for the treatment of chronic hepatitis C in prior interferon monotherapy non-responders (NR)
19. Chronic hepatitis C: Effect of alcohol on hepatitic activity and viral titre
20. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis
21. Low rates of response to interferon in African-Americans with chronic hepatitis C
22. Hepatitis C in African Americans: Summary of a workshop